This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Selecta Biosciences, Inc.
Drug Names(s): SVP-Rapamycin/SVP-Insulin
Description: Selecta is developing a gene therapy that combines SVP-Rapamycin (SEL-110) with SVP-insulin.
Selecta and Sanofi
In October 2014, Selecta and JDRF extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas.
As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells.
SVP-Rapamycin/SVP-Insulin (Sanofi/Selecta) News
Additional information available to subscribers only: